Ratings DRI Healthcare Trust Toronto S.E.

Equities

DHT.U

CA23344H1091

Market Closed - Toronto S.E. Other stock markets 02:21:42 2024-05-02 pm EDT			5-day change	1st Jan Change
11.79 ^USD	-0.51%		-5.00%	+24.11%

May. 06	DRI Healthcare Trust Brief: Q1 Total Income of US$42.1 million; Comprehensive Loss of US$5.0 million; Adjusted Cash Earnings per Unit of US$0.47 (basic and diluted); Net Loss per Unit of US$0.11 (basic and diluted)	MT
May. 06	DRI Healthcare Trust Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company is in a robust financial situation considering its net cash and margin position.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
With an expected P/E ratio at 128.69 and 185.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
DRI HEALTHCARE TRUST	+24.11%	690M	-
ELI LILLY AND COMPANY	+31.52%	690B	C+
NOVO NORDISK A/S	+24.51%	546B	B
JOHNSON & JOHNSON	-5.21%	358B	C+
MERCK & CO., INC.	+17.02%	323B	B-
ABBVIE INC.	+5.01%	287B	C+
ASTRAZENECA PLC	+14.17%	235B	B+
NOVARTIS AG	+4.63%	199B	B-
ROCHE HOLDING AG	-9.90%	195B	A+
AMGEN INC.	+3.98%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes